A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project

R. V. Smalley; J. Carpenter; A. Bartolucci; C. Vogel; S. Krauss

doi:10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M

A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project

R. V. Smalley, J. Carpenter, A. Bartolucci, C. Vogel, S. Krauss

Medicine

Research output: Contribution to journal › Article › peer-review

99 Scopus citations

Abstract

In an ongoing prospective randomized study, 113 evaluable patients have received either a three-drug combination that included cyclophosphamide, adriamycin and 5-fluorouracil (CAF) or a five-drug combination including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) given intermittently 1 week out of 4. Responses (64%), median duration of response (32 weeks), and median duration of disease control (32 weeks) achieved with CAF were superior to those achieved with CMFVP (37%, 22 weeks, 17 weeks, respectively). Morbidity secondary to CAF was significant, with nausea and vomiting, malaise, total alopecia, and granulocytopenia being the main features.

Original language	English (US)
Pages (from-to)	625-632
Number of pages	8
Journal	Cancer
Volume	40
Issue number	2
DOIs	https://doi.org/10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M
State	Published - Aug 1977

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M

Fingerprint

Dive into the research topics of 'A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project'. Together they form a unique fingerprint.

Cite this

Smalley, R. V., Carpenter, J., Bartolucci, A., Vogel, C., & Krauss, S. (1977). A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project. Cancer, 40(2), 625-632. https://doi.org/10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M

A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project. / Smalley, R. V.; Carpenter, J.; Bartolucci, A.; Vogel, C.; Krauss, S.

In: Cancer, Vol. 40, No. 2, 08.1977, p. 625-632.

Research output: Contribution to journal › Article › peer-review

Smalley, RV, Carpenter, J, Bartolucci, A, Vogel, C & Krauss, S 1977, 'A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project', Cancer, vol. 40, no. 2, pp. 625-632. https://doi.org/10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M

Smalley RV, Carpenter J, Bartolucci A, Vogel C, Krauss S. A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project. Cancer. 1977 Aug;40(2):625-632. https://doi.org/10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M

@article{4d2517a4b0a749e1b079b2386f8faaaa,

title = "A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project",

abstract = "In an ongoing prospective randomized study, 113 evaluable patients have received either a three-drug combination that included cyclophosphamide, adriamycin and 5-fluorouracil (CAF) or a five-drug combination including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) given intermittently 1 week out of 4. Responses (64%), median duration of response (32 weeks), and median duration of disease control (32 weeks) achieved with CAF were superior to those achieved with CMFVP (37%, 22 weeks, 17 weeks, respectively). Morbidity secondary to CAF was significant, with nausea and vomiting, malaise, total alopecia, and granulocytopenia being the main features.",

author = "Smalley, {R. V.} and J. Carpenter and A. Bartolucci and C. Vogel and S. Krauss",

year = "1977",

month = aug,

doi = "10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M",

language = "English (US)",

volume = "40",

pages = "625--632",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project

AU - Smalley, R. V.

AU - Carpenter, J.

AU - Bartolucci, A.

AU - Vogel, C.

AU - Krauss, S.

PY - 1977/8

Y1 - 1977/8

N2 - In an ongoing prospective randomized study, 113 evaluable patients have received either a three-drug combination that included cyclophosphamide, adriamycin and 5-fluorouracil (CAF) or a five-drug combination including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) given intermittently 1 week out of 4. Responses (64%), median duration of response (32 weeks), and median duration of disease control (32 weeks) achieved with CAF were superior to those achieved with CMFVP (37%, 22 weeks, 17 weeks, respectively). Morbidity secondary to CAF was significant, with nausea and vomiting, malaise, total alopecia, and granulocytopenia being the main features.

AB - In an ongoing prospective randomized study, 113 evaluable patients have received either a three-drug combination that included cyclophosphamide, adriamycin and 5-fluorouracil (CAF) or a five-drug combination including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) given intermittently 1 week out of 4. Responses (64%), median duration of response (32 weeks), and median duration of disease control (32 weeks) achieved with CAF were superior to those achieved with CMFVP (37%, 22 weeks, 17 weeks, respectively). Morbidity secondary to CAF was significant, with nausea and vomiting, malaise, total alopecia, and granulocytopenia being the main features.

UR - http://www.scopus.com/inward/record.url?scp=0017667562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017667562&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M

DO - 10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M

M3 - Article

C2 - 329975

AN - SCOPUS:0017667562

VL - 40

SP - 625

EP - 632

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -

A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this